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Abstract
Human papillomaviruses have been recognized as the causative agent of anogenital cancer. In 2006, a commercial vaccine based on virus-like
particles composed of the L1 major capsid protein of the papillomaviruses has been available. This vaccine induces virus-neutralizing antibody
responses upon parenteral injection. Here we investigated the oral immunogenicity of different assembly forms of HPV 16 L1, that is: T7-VLPs, T1
particles and capsomeres. Our results show that all three assembly forms induce humoral and cellular immune responses after oral vaccination of
mice. The anti-L1 antibodies were conformation-specific and showed neutralizing activity in a pseudovirion-based assay. We also investigated if
adjuvants have an influence on the oral immunogenicity of the different L1 forms. For saponins we observed a significant toxicity if applied orally.
Co-administration of either CpG DNA or Escherichia coli heat-labile enterotoxin LT(R192G) had no apparent enhancing effect on the production of
anti-L1 antibodies. More pronounced was the effect of CpG administration on the long-term immunity as we observed a significantly stronger recall
response 244 days after the first vaccination. Compared to capsomeres, VLPs induced stronger humoral immune responses while the CTL responses
were induced at comparable levels. Finally, we were also able to induce neutralizing antibodies and L1-specific cytotoxic T-lymphocytes after oral
administration of crude extracts of L1-expressing insect cells. In conclusion, all three assembly forms of the L1 protein are immunogenic when
administered orally.
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The high-risk human papillomaviruses (HPV) have been
associated with a variety of human cancers, including cancers of
the anogenital tract, oropharynx, and non-melanoma skin cancer
(Clifford et al., 2003; Franco et al., 1999; Munoz et al., 2006).
Particularly pronounced is the correlation between HPV 16 and
HPV 18 and cancer of the cervix uteri, as 70% of the cases
contain DNA of these two HPV types (Bosch et al., 1995).
Cervical cancer is the second most common cancer among
women worldwide, with approximately 493,000 cases diag-⁎ Corresponding author. Fax: +49 6221 424932.
E-mail address: Martin.Mueller@dkfz.de (M. Müller).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.08.004nosed resulting in 274,000 deaths worldwide every year, and
therefore constitutes a major disease burden (Parkin et al., 2005;
Pisani et al., 2002). The discovery that the expression of the
major capsid protein L1 of papillomaviruses in different
expression systems (e.g. insect cells or yeast) leads to the self-
assembly of virus-like particles (VLPs) initiated several studies.
These demonstrated that systemic immunization with VLPs in
the animal model induces the generation of neutralizing
antibodies and L1-specific cytotoxic T-lymphocytes (CTLs)
and protects animals challenged with the corresponding PV type
(Gissmann et al., 2001; Schiller and Davies, 2004; Schiller and
Lowy, 2001). This was the basis for the development of two
highly efficient VLP-based HPV vaccines named Gardasil
(Merck MSD), which has been commercially available since
2006, and Cervarix (GlaxoSmithKline), which was recently
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available by end of this year (Harper et al., 2004; Lowy and
Schiller, 2006; Villa et al., 2006). The major drawbacks of these
vaccines are the high production costs and the need for a cold
chain and sterile needles for the intramuscular administration.
Both of these hamper widespread distribution in developing
countries, where over 80% of the cervical cancer cases occur.
An economically advantageous alternative to VLP-based
vaccines might be the use of L1 pentamers (capsomeres),
which can be easily purified from Escherichia coli and have
been shown to induce a protective systemic immune response
after parenteral administration (Ohlschlager et al., 2003; Rose et
al., 1998; Yuan et al., 2001). Furthermore, alternative
immunization routes have been investigated and many
examples demonstrating the efficiency of mucosal immuniza-
tion for different antigens are described in the literature (Aziz et
al., 2007; Holmgren and Czerkinsky, 2005; Neutra and
Kozlowski, 2006). Indeed, intranasal as well as oral adminis-
tration of VLPs was proven to induce neutralizing antibodies
and L1-specific CTLs (Balmelli et al., 1998; Dupuy et al., 1999;
Gerber et al., 2001; Rose et al., 1999). An additional advantage
of mucosal immunization methods is the induction of secretory
IgA (sIgA) antibodies at the site of infection, as it is not clear
how efficiently parenteral administration of L1-particles can
provoke the generation of these antibodies in the genital tract
(Kozlowski et al., 1999; Mestecky et al., 1994; Nardelli-
Haefliger et al., 1999).
In this study, we aim to determine whether the advantages of
capsomeres can be combined with mucosal immunization
procedures by investigating the oral immunogenicity of
different HPV 16 L1 assembly forms. Our experiments indicate
that oral application of T7-VLPs (72 pentamers), T1 particles
(12 pentamers) and even capsomeres induces the production of
neutralizing antibodies and L1-specific CTLs in mice. Evalua-
tion of CpG DNA, E. coli heat-labile enterotoxin LT(R192G)
and crude saponins as mucosal adjuvants, in combination with
VLPs or capsomeres, showed only a significant enhancing effect
of CpG DNA on the long-term immune response. Taking one
step further in the direction of low-cost vaccines that requireFig. 1. Analysis of different L1 assembly forms by electron microscopy. Capsomeres
wild-type HPV 16 L1 gene (L1_wt) or a mutated L1 (L1_2xCysmut), dialyzed againonly a few processing steps, we also show that oral immuniza-
tion with crude lysates of HPV 16 L1-expressing insect cells
induces the generation of neutralizing antibodies and L1-specific
CTLs.
Results
Virus-like particles (VLPs) are prime vaccine candidates to
induce neutralizing antibody responses after subcutaneous (s.c.)
or intramuscularly (i.m.) immunization (Breitburd and Coursa-
get, 1999; Lowy and Schiller, 2006). Furthermore, it has been
shown in several studies that VLPs are also potent antigens after
intranasal (i.n.) or oral application, which might provide an
alternative, non-invasive route of vaccination (Gerber et al.,
2001; Liu et al., 1998; Nardelli-Haefliger et al., 1999; Rose et al.,
1998). It has also been demonstrated that s.c., i.m., i.p., or i.n.
application of capsomeres induces systemic humoral and cellu-
lar immune responses (Dell et al., 2006; Fligge et al., 2001;
Ohlschlager et al., 2003; Rose et al., 1998). In this study we
analyzed if HPV 16 L1 capsomeres can also be used as an oral
vaccine to provoke the generation of L1-specific neutralizing
antibodies and cytotoxic T-lymphocytes.
Oral application of HPV 16 L1 VLPs, T1-particles and
capsomeres induces L1-specific IgG and IgA antibodies
The wild-type HPV 16 L1 gene (L1_wt) and a mutated L1
(L1_2xCysmut: C175A+C428A), encoding a protein that lacks
two cysteine residues that are important for VLP assembly (Sapp
et al., 1998), were expressed in insect cells using recombinant
baculoviruses. The L1_wt gene gave rise to virus-like particles
with a T7 structure (VLPs), whereas expression of the
L1_2xCysmut gene resulted in the production of capsomeres
(L1 pentamers) and small particles with a T1 structure (T1-
particles; Fig. 1). The different HPV 16 L1 assembly forms
(VLPs, T1-particles and capsomeres) were purified by CsCl
density centrifugation and mice (five female BALB/c mice per
group) were immunized orally four times (on days 0, 14, 28, and
231) with 100 μg L1 protein in the presence or absence of CpG, T1-particles and VLPs were purified out of infected insect cells expressing the
st water and after negative staining analyzed by electron microscopy.
Fig. 2. Oral application of VLPs, T1-particles or capsomeres induces the production of neutralizing antibodies. Female BALB/c mice (five mice per group) were immunized orally with 100 μg VLPs, T1-particles or
capsomeres in the presence or absence of CpG DNA as an adjuvant or with CpG DNA alone on days 0, 14, 28 and 231, and blood samples were collected on days 35 and 244. The reciprocal titers of L1-specific IgG
antibodies on days 35 (A) and 244 (B) were determined by VLP-capture ELISA. Additionally, the neutralization capacity of the sera was analyzed at a 1:250 dilution and %neutralization is shown for days 35 (C) and 244
(D). Each bar represents one mouse. The IgG titers and neutralization capacity of three mice (mice 2 and 5 of the group ‘capsomere+CpG’ and mouse 2 of the group ‘VLP+CpG’) on day 244 could not be determined.
n.t.: not tested.
377
N
.
T
hönes,
M
.
M
üller
/
Virology
369
(2007)
375–388
Table 1
Oral immunization with three different assembly forms of HPV 16 L1
Immunogen IgG titer
(day 35)
% neutralization
(day 35)
IgG titer
(day 244)
% neutralization
(day 244)
Serum IgA titer
(day 244)
Secreted IgA
(day 244)
ELISPOT
(day 244)
CpG only median 0 19 0 0 0 0.240 12
IQR 0–0 0–47 0–0 0–0 0–0 0.239–0.263 10–16
caps+CpG median 3200 92 25,600 94 1280 0.508 26
IQR 800–3200 91–95 19,200–38,400 90–96 645–1280 0.407–1.094 15–154
T1+CpG median 800 56 25,600 91 320 0.797 147
IQR 800–1600 15–67 12,800–51,200 83–96 160–2560 0.588–1.434 22–380
VLPs w/o CpG median 3200 98 3200 93 80 0.397 58
IQR 1600–3200 98–99 800–3200 91–101 80–160 0.392–0.486 21–62
VLPs+CpG median 6400 101 51,200 106 7680 3.099 194
IQR 3200–12,800 100–101 41,600–51,200 104–108 4480–10,240 2.895–3.188 111–291
The table summarizes humoral and cellular immune responses of the different immunization groups. For antibodies, the titer of serum IgG and IgA is shown, for
secreted IgA the ELISA signal of vaginal wash samples is indicated. Neutralizing activity is shown as percentage neutralization relative to a positive control. Reactivity
in ELISPOT is shown as number of IFN-γ spots per 106 cells after stimulation with VLPs. IQR: interquartile range.
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DNA served as a negative control. Blood samples from days 35
and 244were analyzed by L1-capture ELISA.Whereas in sera of
the control mice no L1 antibodies could be detected, all mice
immunized with L1-particles developed specific IgG antibodies
until day 35 with titers reaching a maximum of 12,800 (Fig. 2A
and Table 1,). Sera of mice immunized with capsomeres and
adjuvants showed a median titer of 3200 (interquartile range
800–3200), sera of T1-particles immunized mice showed a
median titer of 800 (interquartile range 800–1600). In contrast,
sera of mice immunized with VLPs plus adjuvants showed a
median titer of 6400 (interquartile range 3200–12800), however,
these differences are not statistically significant. At day 244,
13 days after receiving the third booster immunization, the titers
were further increased (up to 51,200) and the differences
between the groups immunized with different L1-assembly
formswere less evident (Table 1, Fig. 2B).Mice immunizedwith
VLPs, in combination with CpG DNA, developed higher titersFig. 3. Oral immunization induces high titers of neutralizing antibodies. Female BA
DNA on days 0, 14, 28 and 231, and blood samples were collected on day 244. Resu
11, 14 (immunized with T1-particles), 21 and 24 (immunized with VLPs) were testcompared to mice immunized with VLPs in the absence of
adjuvant. This effect was noticeable on day 35 (VLPs w/o CpG:
median 3200; VLPs+CpG: median 6400) and became even
more evident on day 244 (VLPs w/o CpG: median 3200; VLPs+
CpG: median 51,200; p=0.0317), indicating that CpGDNA as a
mucosal adjuvant is able to enhance the long-term immune
response.
Thirteen of 20 sera collected at day 35 (Fig. 2C) and all sera
from day 244 (Fig. 2D) were able to neutralize HPV 16
pseudovirions in the neutralization assay developed by Buck
et al. (2004) if tested in an 1:250 dilution. Additionally, selected
sera were titrated in the neutralization assay. As shown in Fig. 3,
sera of mice immunized with capsomeres (mouse 8), T1-
particles (mice 11 and 14) or VLPs (mice 21 and 24) reached
titers between 16,000 (mice 8 and 11) and higher than 32,000
(mice 14, 21, and 24). In conclusion, oral application of VLPs,
T1-particles and even capsomeres induces L1-specific neutraliz-
ing antibodies.LB/C mice were immunized with 100 μg L1 protein in combination with CpG
lts are shown for selected animals. Sera of mice 8 (immunized with capsomeres),
ed in different dilutions in a neutralization assay with HPV 16 pseudovirions.
379N. Thönes, M. Müller / Virology 369 (2007) 375–388As one advantage of oral immunization compared to systemic
immunization is the induction of mucosal IgA antibodies
(Nardelli-Haefliger et al., 1999), sera and vaginal wash samples
of the immunized mice from day 244 were screened for the
presence of L1-specific IgA antibodies. Sixteen out of the 17
mice immunized with the L1 protein developed specific IgA
antibodies in the serum with titers reaching a maximum of
10,240 (Table 1, Fig. 4A). Similar to the IgG response, there
were also differences in the IgA response after immunization
with different L1 assembly forms (median of different groups:
capsomeres: 1280; T1-particles: 320; VLPs: 7680). Addition-
ally, we were able to detect L1-specific secreted IgA antibodies
in 14 out of 17 vaginal wash samples with signals above the
background level (reactivity in the negative control group;
Table 1, Fig. 4B). The enhancing effect of CpG DNA on the
immune responsewas also reflected by the IgA response (median
of IgA titer in serum: VLPs w/o CpG: 80 vs. VLPs+CpG: 7680,Fig. 4. Detection of L1-specific IgA antibodies in serum and vaginal wash samples a
(five mice per group) were orally immunized with 100 μg VLPs, T1-particles or capso
alone on days 0, 14, 28 and 231. On day 244, blood and vaginal wash samples were
antibodies in the sera on day 244. (B) Analysis of vaginal wash samples in VLP-capt
represents one mouse. For three mice (mice 2 and 5 of the group ‘capsomere+CpG’ a
IgA could not be determined. n.t.: not tested.p=0.0159; median of IgA signal in vaginal wash samples: VLPs
w/o CpG: 0.397 vs. VLPs+CpG: 3.099, p=0.0317).
Oral application of HPV 16 L1 VLPs, T1-particles and
capsomeres induces L1-specific T-cell responses
Besides the humoral immune response, the mice were also
analyzed with respect to the T-cell response. Splenocytes of the
immunized mice were collected 10 days after the fourth immu-
nization (day 244) and analyzed in an ex vivo interferon-γ
ELISPOT. As a cytotoxic T-cell epitope of HPV 16 L1 for the
H2-b haplotype of BALB/c mice has so far not been described,
we used VLPs to stimulate the Tcells in the ELISPOTassay. The
use of VLPs as antigen, however, does not allow discriminating
between CD4 and CD8 restricted T-cell responses. As negative
control, the splenocytes were stimulated with a mock control
(‘VLP’-purification from insect cells expressing L2 instead offter oral immunization with different L1-assembly forms. Female BALB/c mice
meres in the presence or absence of CpG DNA as an adjuvant or with CpG DNA
collected and analyzed in a VLP-capture ELISA. (A) Titers of L1-specific IgA
ure ELISA. Shown is the ELISA signal at a 1:5 dilution of the samples. Each bar
nd mouse 2 of the group ‘VLP+CpG’), the IgA titer and the amount of secreted
Fig. 5. Detection of L1-specific T-lymphocytes with an interferon-γ ELISPOT. Female BALB/c mice (five mice per group) were immunized orally with 100 μg VLPs,
T1-particles or capsomeres in the presence or absence of CpG DNA as an adjuvant or with CpG DNA alone on days 0, 14, 28 and 231. On day 244 the splenocytes of
the mice were collected and analyzed in an interferon-γ ELISPOT. The graph shows the number of spots per 1*106 cells after stimulation with VLPs. Each bar
represents one mouse. The values of three mice (mice 2 and 5 of the group ‘capsomere+CpG’ and mouse 2 of the group ‘VLP+CpG’) are not available. n.t.: not tested.
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cell proteins (data not shown). The assay demonstrates that oral
immunization with any of the three L1 assembly forms induced
L1-specific T-cell responses in 12 of 17 mice (Fig. 5), which
were detectable by ex vivo ELISPOT even without further
restimulation of the lymphocytes. Similar to the antibody
response, the T-cell response was enhanced in those mice
treated with CpG DNA as adjuvant, although the differences
were not statistically significant (median of spot numbers: 58
(VLPs w/o CpG) vs. 194 (VLPs + CpG); Table 1, Fig. 5).
Different adjuvants for oral immunization with HPV 16 L1
capsomeres or VLPs
Because of the observed enhancing effect of CpG DNA, we
decided to investigate the influence of other adjuvants on the
immune response after oral application of L1 VLPs and cap-
someres. In addition to CpG DNA, we also used LT(R192G), a
genetically detoxified derivative of the E. coli heat-labileTable 2
Oral immunization with HPV 16 capsomeres and VLPs in combination with differe
Immunogen Adjuvant IgG titer
Median IQ
Capsomeres w/o 75 0–
CpG DNA 100 0–
LT(R192G) 0 0–
saponin 0 0–
VLPs w/o 1200 225–
CpG DNA 25,600 125–
LT(R192G) 4400 1800–
saponin 525 201–
negative ctrl (L2) CpG/LT(R192G) 0 0–
VLPs s.c. CpG 204,800 204,800–
The table summarizes the median and the interquartile ranges of the IgG titers and ce
shown as number of IFN-γ spots per 106 cells after stimulation with an L1 H2b resenterotoxin (Freytag and Clements, 1999) and crude saponins
(Pickering et al., 2006). AsMHC class I restricted T-cell epitopes
of HPV 16 L1 for the H-2d haplotype of the BALB/c mice have
not been described, we used C57BL/6 mice in a second
immunization study. These mice can be tested in an interferon-γ
ELISPOT by stimulation with the HPV 16 L1(165–173) peptide, a
HPV 16 L1 MHC class I T-cell epitope in the H-2b haplotype
(Ohlschlager et al., 2003).
Five C57BL/6 mice per group were immunized orally with
50 μg insect cell-derived capsomeres or VLPs without adjuvant
or in combination with CpG DNA, LT(R192G) or saponins. Six
mice received the mock purified protein in the presence of the
different adjuvants as a negative control and five mice were
immunized s.c. with 10 μg VLPs and CpG DNA as positive
control. In total, the mice were immunized five times biweekly
and blood samples were collected before the first, and 1 week
after each immunization. During the course of the experiment we
observed toxic effects of the saponins (2.5 mg per dose), as 6 of
the 12 saponin treated mice died.nt adjuvants
% neutralization ELISPOT
R Median IQR Median IQR
1200 0 0–0 5 3–20
400 0 0–0 23 4–24
50 16 12–21 9 6–21
0 26 19–33 0 0–0
2000 89 12–97 2 1–4
51,200 95 38–96 15 7–26
209,600 97 76–97 13 5–32
888 20 16–25 0 0–3
0 0 0–0 1 0–3
409,600 95 94–95 43 37–50
llular responses of the different immunization groups. Reactivity in ELISPOT is
tricted peptide. IQR: interquartile range
Fig. 6. Development of IgG titers after oral application of capsomeres or VLPs in combination with different adjuvants. C57BL/6 mice (5 mice per group) were
immunized orally with 50 μg of HPV 16 L1 capsomeres or VLPs without adjuvant or in combination with CpG DNA, LT(R192G) or saponin. Control groups were
immunized with adjuvant alone or s.c. with 10 μg VLPs in combination with CpG DNA. In total, five immunizations were performed in 2-week intervals, and every
other week, blood samples were collected and analyzed inVLP-capture ELISA and neutralization assaywithHPV16 pseudovirions. Reciprocal titers of L1-specific IgG
antibodies (A) and %neutralization at a serum dilution of 1:100 (B) are shown for the mouse sera after the final immunization. Each bar represents one mouse. (C)
Development of the IgG titer in dependence on the number of immunizations. The IgG titers from the blood samples collected before the first immunization (week −1)
and after every boost (weeks 1, 3, 5, 7 and 10) were determined and plotted against the different time points. Animals for which not all IgG titers could be determined are
not shown. Groups with less than five animals are: negative control (4 mice), capsomeres+saponin (2 mice), VLPs+LT(R192G) (4 mice) and VLPs+saponin (4 mice).
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(Table 2 and Fig. 6A) confirmed that oral application of
capsomeres or VLPs induced the generation of L1-specific
antibodies which were consistently able to neutralize HPV 16
pseudovirions (Table 2 and Fig. 6B). The co-administration of
saponins with L1-particles had not only a toxic side effect but
actually decreased the immune response (median titers were 75
for capsomeres without adjuvants, 1200 for VLPs without
adjuvants, 0 for capsomeres plus saponins, and 525 for VLPs
plus saponins; Table 2, Fig. 6A). The reduced number of animals
in the saponin group, however, does not allow determining
statistical significance of the influence of the adjuvants. Neither
CpG DNA nor LT(R192G) showed a significant adjuvant effect
if administered in combination with capsomeres or VLPs. After
five immunizations, 15 out of the 18 VLP-immunized mice, but
only 8 out of the 17 capsomere-immunized mice, developed
specific IgG antibodies. The titers after administration of
capsomeres were between 50 and 1200, except for one mouse
that reached a titer of 51,200. In contrast, mice vaccinated with
VLPs showed titers between 50 and 51,200, and onemouse even
reached a titer of 819,200. Analyzing sera collected at different
time points revealed that on average, mice immunized with
VLPs generated L1-specific IgG antibodies faster than mice
immunized with capsomeres (Fig. 6C). While in VLP-
immunized mice L1-specific antibodies were detected as early
as 1 to 3 weeks, the response in capsomere immunized mice
required at least 5 weeks.
Two weeks after the fifth immunization, the splenocytes of
the mice were analyzed in an ex vivo ELISPOT after stimulation
with the HPV 16 L1(165–173) peptide. Eight of the 17 mice
immunized with capsomeres and 7 of the 18 mice that received
VLPs orally were positive (Fig. 7). In contrast to the IgG titers,
there was no clear difference in CTL responses in the miceFig. 7. Detection of L1-specific CTLs after five oral immunizations with capsomeres o
HPV 16 L1 capsomeres or VLPs without adjuvant or in combination with CpG DNA
s.c. with 10 μg VLPs in combination with CpG DNA. Two weeks after the last of fi
peptide and analyzed in an interferon-γ ELISPOT. Shown are the numbers of spots pe
are: negative control (4 mice), capsomeres+saponin (2 mice), VLPs+LT(R192G) (immunized with the different L1-assembly forms. In general,
compared to immunization experiment which was performed in
BALB/c mice, we observed a weaker antibody response in the
C57BL/6 mice. To investigate whether the immune response is
mouse strain dependent, we immunized BALB/c, C57BL/6 and
Swiss Webster mice with 50 μg of insect cell derived VLPs.
Evaluation of the IgG titers indicated that oral immunization of
BALB/c mice was more efficient than that of C57BL/6 mice,
however, due to the size of the groups, the differences were
statistically not significant (data not shown).
Oral immunization with L1-containing crude insect cell
extracts induces neutralizing antibodies and L1-specific CTLs
A major advantage of oral immunization is that antigens do
not need to be applied in a highly purified state. This would
allow the use of, after a few simple processing steps, antigen-
containing extracts of plants, yeast cells, E. coli, for oral
immunization. To analyze if crude extracts of insect cells
containing the L1 protein induce neutralizing antibodies after
oral administration, C57BL/6 mice were immunized with
different doses of infected High Five cells (0.5, 1 or 2*107
cells) expressing the wild-type HPV 16 L1 gene without
adjuvants or in combination with CpG DNA. We estimated the
L1 content in the extracts to be 100–150 μg per 1*107 cells
(data not shown). In the control group, mice received 2*107
High Five cells infected with wild-type baculovirus in
combination with CpG DNA. In total, the mice were immunized
five times at 2-week intervals, blood samples were collected
8 days after the last boost and were analyzed by ELISA. In 9 out
of the 15 mice receiving L1-expressing cells, VLP-specific IgG
antibodies were detected with titers reaching a maximum of
6400. Comparison of the IgG titers of groups immunized withr VLPs. C57BL/6 mice (5 mice per group) were immunized orally with 50 μg of
, LT(R192G) or saponin. Control groups were immunized with adjuvant alone or
ve immunizations, the splenocytes were stimulated with the HPV 16 L1(165–173)
r 1*106 cells. Each bar represents one mouse. Groups with less than five animals
4 mice) and VLPs+saponin (4 mice).
Fig. 8. Detection of neutralizing antibodies after oral immunization with crude cell lysates. C57BL/6 mice (three mice per group) were immunized orally with crude
lysates of High Five cells expressing the wild-type HPV 16 L1 gene. The different groups received 0.5, 1, or 2*107 cells without adjuvant or in combination with CpG
DNA. Control mice were immunized mock infected High Five cell extracts. After four immunizations in 2-week intervals, serum samples were collected and analyzed
in VLP-capture ELISA and neutralization assay. Shown are reciprocal titers of L1-specific IgG antibodies in the serum (A) and the neutralization capacity of the sera at
a 1:00 dilution in %neutralization (B). Each bar represents one mouse. Wt: High Five cells infected with wild-type baculovirus (2*107 cells+CpG DNA).
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effect nor an adjuvant effect after co-administration of CpG
DNA (Fig. 8A). Surprisingly, the group of mice immunized with
the highest cell number in combination with CpG DNA showed
the lowest IgG titers. All anti-L1-positive sera were able to
neutralize HPV 16 pseudovirions (Fig. 8B), leading to the
conclusion that not only the application of purified L1-particles
but also of crude cell extract containing L1 can induce
conformation specific, neutralizing antibodies.
In addition to the humoral immune response, L1-specific
cytotoxic T-lymphocytes were also induced in 10 out of the 15
mice inoculated with L1-containing cell extracts, as shown by
analysis of splenocytes taken after the fifth immunization in an
ex vivo ELISPOT using the HPV 16 L1(165–173) peptide
(Fig. 9). Again, there was no dose-dependency for the cellular
immune response, as only one of the strongly reacting mice was
immunized with the highest cell number (2*107 cells; Fig. 9).
Discussion
In addition to intranasal application, oral vaccination is the
most important non-invasive alternative to systemic immuniza-tion. In this study we evaluated the oral immunogenicity of
different assembly forms of HPV 16 L1. It has been demon-
strated previously that VLPs are able to induce neutralizing
antibodies if administered orally (Gerber et al., 2001; Rose et al.,
1999). Going one step further, we have been able to show that, in
two independent immunization experiments, T1-particles and
capsomeres also lead to the production of neutralizing
antibodies, secreted IgA and L1-specific cytotoxic T-lympho-
cytes after oral administration. Interestingly, all the mice in the
first immunization series but only about 65% of the orally
immunized mice in the second experiment developed L1-
specific antibodies. One possible reason for this observation
could be that, in the first experiment, the amount of administered
L1 protein was higher (100 μg instead of 50 μg L1 protein).
Nevertheless, it has been reported in the literature that as little as
1–10 μg of VLPs are sufficient to induce high titers of L1-
specific antibodies after oral application (Gerber et al., 2001).
The lower efficiency in our hands, especially in the second
immunization experiment, could be due to differences in protein
preparation, determination of the protein concentration, oral
application method or even conditions of animal housing.
Furthermore, efficiency of oral immunization might very well
Fig. 9. Detection of L1-specific CTLs after oral immunization with crude cell lysates of L1-expressing High Five cells. C57BL/6 mice (three mice per group) were
immunized orally with crude lysates of High Five cells expressing the wild-type HPV 16 L1 gene. The different groups received 0.5, 1, or 2*107 cells without adjuvant
or in combination with CpG DNA. Control mice were immunized mock infected High Five cell extracts. Ten days after the last of four immunizations, the splenocytes
were collected, stimulated with the HPV 16 L1(165–173) peptide and analyzed in an interferon-γ ELISPOT. Shown are spot numbers per 1*10
6 splenocytes. Each bar
represents one mouse. Wt: High Five cells infected with wild-type baculovirus (2*107 cells+CpG DNA).
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inbred mouse strains show differences in their immune response
if exposed to the same stimulus (De Maio et al., 1998; O'Malley
et al., 1998; Stewart et al., 2002). Therefore, we presume that the
immune response after administration of HPV 16 L1-particles
might also differ between the two mouse strains. This could
explain why the C57BL/6mice, whichwere immunized orally in
the second experiment, developed antibodies with much lower
efficiency compared to the BALB/c mice in the first immuniza-
tion series or the data published by others (Gerber et al., 2001;
Rose et al., 1999).
A discrepancy we observed in comparison to earlier studies
was the low adjuvant effect of CpG DNA and LT(R192G) if
administered orally in combination with VLPs or capsomeres to
C57BL/6 mice. Again, this could be linked to the mouse strain,
as other studies have been performed using BALB/cmice, or to a
different handling of the adjuvants. Nevertheless, we observed a
significant effect of CpG DNA on the long-term immune
response if administered in combination with VLPs to BALB/c.
The observed adjuvant effect is probably due to interaction of the
CpG ODN with Toll-like receptor 9 molecules (TLR9), which
are expressed by several cell types in the gastrointestinal tract
including not only immune cells but also gastric epithelial cells,
villus enterocytes, and Paneth cells (Watson and McKay, 2006).
However, it is remarkable that, in the prokaryotic environment of
the gastrointestinal tract, CpG ODN still have immune-
stimulating effects. This might be due to the higher stability of
the modified CpG motifs but it is also possible that the CpG
ODN are able to directly bind to the positively charged surface of
capsomeres and VLPs.
In our study, the application of VLPs could induce the
production of specific antibodies with higher efficiency than
capsomeres. This is consistent with other publications reporting
a higher immunogenicity of VLPs after intraperitoneal injection(Fligge et al., 2001). Because E. coli-derived capsomeres are
considered to be a cost-effective alternative to VLPs derived
from eukaryotic cells for the development of a second-
generation HPV vaccine, the differences in immunogenicity
should be analyzed in more detail.
Nevertheless, it is noteworthy that even structures as small as
capsomeres, after exposure to the low pH and proteolytic activity
of the stomach, are still able to be presented to the immune
system in a conformation-specific manner leading to the in-
duction of functional, neutralizing antibodies.
A remaining controversy is if systemic immunization is able
to induce the production of secreted IgA antibodies in the genital
tract (Kozlowski et al., 1999; Liu et al., 1998; Mestecky and
Russell, 2000; Nardelli-Haefliger et al., 1999). Generally, it is
assumed that mucosal immunizationmight bemore suitable, and
that intranasal immunization especially leads to the production
of high levels of secreted IgA antibodies in the vaginal tract
(Holmgren and Czerkinsky, 2005). In our experiments, we
observed the induction of secreted IgA antibodies after oral
immunization, but not after subcutaneous immunization,
strengthening the assumption that mucosal immunization
comes with the added benefit of inducing local immune
responses. Comparison of subcutaneous, intranasal and oral
immunizations with purified proteins leads to the conclusion that
the quality of the induced immune response is comparable,
although oral application is the least efficient route.
Despite a definite need for improving its efficiency, oral
vaccination could be an attractive alternative route of immuniza-
tion. Of special interest is the concept of using transgenic plants
as edible vaccines. A number of clinical studies demonstrated
the induction of specific antibodies after oral immunization
using crude plant material containing, for example, hepatitis B or
Norwalk virus antigens (reviewed by Lal et al., 2007). Further-
more, it has been reported for HPV 16 that oral immunization
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can induce specific antibodies (Biemelt et al., 2003; Sasagawa
et al., 2005). Our study confirms these results using L1-
expressing High Five cells and additionally shows the induction
of L1-specific cytotoxic T-lymphocytes.
One disadvantage of the current commercial HPV vaccines,
which renders the application in developing countries particu-
larly difficult, is that, in total, three subsequent systemic
immunizations are required. We observed in this study that
oral immunization can lead to high antibody titers if a sufficient
number of booster immunizations is applied. It was described
earlier that systemic prime/oral boost protocols induce efficient
immune responses (Lauterslager et al., 2001, 2003). One could
imagine a setting in which long-term immunity, post initial
immunization, is maintained by an oral booster strategy. We are
currently investigating the possibility of using oral boosting to
maintain long-term immunity against HPV capsid antigens.
Materials and methods
Purification of HPV 16 L1-particles
For the production of the different L1 assembly forms,
recombinant baculoviruses containing the wild-type HPV 16 L1
(L1_wt) gene or a mutated L1 (L1_2xCysmut: C175A+C428A)
gene were used. High Five insect cells (Invitrogen, Germany)
were grown as suspension cultures at 27 °C in 250 ml Ex-Cell
405 serum-free medium (JRH Biosciences, USA) in a spinner
flask until they reached a density of 2*106 cells/ml. They were
then infected for 3 days with recombinant baculoviruses as
previously described (Muller et al., 1997). Cell pellets were
resuspended in 20 ml of extraction buffer (5 mM MgCl2, 5 mM
CaCl2, 1 M NaCl, 0.01% Triton X-100, 20 mM Hepes pH 7.4
and 1mMPMSF) and the proteins were extracted using a French
Press. The lysate was cleared by centrifugation at 47,800×g at
4 °C for 40 min and the resultant supernatant was loaded on a
two-step gradient consisting of 7 ml sucrose (30%w/v) on top of
7 ml CsCl (58% w/v), followed by a centrifugation at 96,500×g
at 10 °C for 3 h in a SW32 rotor (Beckman Ultracentrifuge). The
interphase between the sucrose and CsCl and the CsCl layer was
mixed and transferred into Quickseal tubes (Beckman, USA).
After another centrifugation step of 16–18 h at 20 °C at
184,000×g in a Beckman TFT 65.13 rotor, the tubes were
punctured in the bottom with 20-gauge needles and 1-ml
fractions were collected. These were analyzed by antigen
capture ELISA and Western blot analysis to determine the L1-
containing fractions. The structure of the particles was
determined by electron microscopy (Muller et al., 1997).
Preparation of L1-particles for vaccination
For oral immunization purified L1-particles were dialyzed
against 20 mM Hepes (pH 7.4), 0.5 M NaCl before use. The
concentration was determined by comparing different dilutions
of the L1 stock solutions with BSA standards (2, 1, 0.5, 0.25 and
0.125 μg/μl) in Bradford assay and Coomassie gel analysis. For
oral immunization, 50 or 100 μg were diluted in a final volume
of 200 μl phosphate buffered saline (PBS) either with or withoutan adjuvant. For s.c. immunization, 10 μg VLPs, in combination
with 10 μg CpG DNA, were diluted in a final volume of 100 μl
PBS.
Preparation of crude cell extracts for vaccination
High Five cells were infected with recombinant baculovirus
encoding the L1_wt gene as described above for 3 days.
Afterwards, the cells were collected, counted and frozen in
aliquots at −80 °C. The L1 amount in the infected cells was
estimated by Western blot analysis using defined cell numbers
and comparing the L1 signal with control samples containing
purified L1 protein. Immediately before use, the cells were
thawed and resuspended in a final volume of 200 μl PBS
containing a total of 0.5, 1 or 2*107 cells.
Adjuvants
CpG DNA (CpG ODN 1826; 5′-TCCATGACGTTCCT-
GACGTT-3′) (Walker et al., 1999) was synthesized with a
nuclease-resistant phosphorothioate backbone. 10 μg CpGDNA
were applied per dose. E. coli LT(R192G), a genetically
detoxified derivative of the E. coli heat-labile enterotoxin, was
kindly provided by J.D. Clements (Tulane University, New
Orleans, LA). Lyophilized LT(R192G) was reconstituted in
sterile PBS (1 mg/ml) and 10 μg were applied per dose. Crude
saponins (Saponin from Quillaja bark, Sigma, Germany) were
dissolved in PBS to a final concentration of 50mg/ml and 2.5mg
were applied per dose.
Immunization of mice
Six- to 8-week-old BALB/c and C57BL/6 mice were pur-
chased fromCharles RiverWiga breeding laboratories (Sulzfeld,
Germany) and maintained under specific pathogen-free condi-
tions. All animal experiments were approved by the Regierung-
spräsidium Karlsruhe (G67/02 and G62/06). The mice were
immunized intragastrically with 200 μl of the corresponding
vaccine using a gavage, and control mice were injected s.c. with
100 μl vaccine. Sera were collected from anesthetized animals
via retro-orbital sinus puncture at the indicated time points, and
8–14 days after the last immunization, final blood was collected
by cardiac puncture. Vaginal wash samples were gained by
rinsing the vagina of anesthetized mice with 100 μl PBS. The
wash samples were stabilized by adding 10 mM phenylmetha-
nesulphonylfluoride (PMSF) after the collection.
Detection of antibodies by VLP-capture ELISA
The presence of L1-specific IgG and IgA antibodies in sera
and vaginal wash samples of mice was determined by VLP-
capture ELISA. 96-Well assay plates (Becton Dickinson, USA)
were coated overnight at 4 °C with Protein G purified polyclonal
rabbit IgG (blocked against insect cell and baculovirus proteins)
specific for HPV 16 VLPs (85 ng in a volume of 50 μl/well). All
following incubation steps were carried out for 1 h at 37 °C,
antigens and antibodies were diluted in blocking solution (3%
skimmed milk in PBS/Tween-20 0.3%), and each step was
followed by washing three times with PBS/T (PBS with 0.3%
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solution per well, 350 ng VLPs in blocking solution were added
to the wells (50 μl/well). The mouse sera were diluted 1:50 or
titrated up to 1:812,000, whereas vaginal wash samples were
diluted 1:5 (50 μl/well). As secondary antibodies 50 μl per well
of either IgG- (goat anti-mouse IgG, conjugated with Dianova,
Germany) or IgA-specific (goat anti-mouse IgA, conjugated
with horseradish peroxidase; Southern Biotechnology, USA)
diluted 1:3000 or 1:5000, respectively, were added. After
incubation with the secondary antibody, plates were washed
six times with PBS/T and 100 μl freshly prepared staining
solution (100 mM NaAc, 50 mM NaH2PO4, pH 4.2, 1 mg/ml
ABTS (2,2′-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid),
0.012% H2O2) were added. Ten to 20 min later absorbance was
measured at 405 nm using a Titertek plate reader. Endpoint
titers were determined as the reciprocal of the highest serum
dilution giving an absorbance value greater than the average
absorbance of negative control mice plus three times the
standard deviation (values between 0.1 and 0.2).
Production of HPV 16 pseudovirions and neutralization assay
Production of pseudovirions was performed by cotransfec-
tion of 293TT cells with a plasmid containing the humanized
HPV 16 L1 and L2 genes and an SV40 origin (pCDNA4-
HPV16L1h-IRES-L2h/SV40ori), together with a second plas-
mid encoding the reporter protein secreted alkaline phosphatase
under the control of the CMV promotor (pCMVSEAP)
following a procedure described earlier (Pastrana et al., 2004).
7*106 293TT cells were seeded on 10-cm culture dishes in
DMEM (Sigma, Germany), supplemented with 10% FCS
(Gibco BRL, Germany), 1% penicillin/streptomycin (Life
Technologies, Germany) and 125 μg/ml hygromycin (Roche)
18 h in advance. The cotransfection was performed using
METAFECTENE™ (Biontex, Germany) according to the
manufacturer's instructions with minor changes. 15 μg of both
plasmids were mixed with 70 μl METAFECTENE™, incubated
for 20 min and added to the cells. After 5 h, a medium change
was performed and the cells were incubated at 37 °C for 3–
4 days. For pseudovirion extraction, the cells were harvested by
trypsination, washed once with PBS and resuspended in 1 ml
modified PBS (containing 1 mMCaCl2 and 5.6 mMMgCl2) per
5*107 cells. After addition of 4 μl Benzonase (250 U/ml, Sigma,
Germany) and 50 μl Brij58 (Sigma, Germany), cells were
incubated on ice for 5 min, followed by the addition of NaCl to a
final concentration of 710 mM to induce the maturation of the
pseudovirions during a 10-min incubation at 4 °C. The cellular
lysate was cleared by centrifugation (10 min at 3500×g) and the
pseudovirions were stored at −70 °C.
As target cells for the neutralization assay, 293TT cells were
seeded at a concentration of 22,500 cells per well on 96-well
plates in DMEM (Sigma, Germany), supplemented with 10%
FCS (Gibco BRL, Germany), 1% penicillin/streptomycin (Life
Technologies, Germany) and 125 μg/ml hygromycin (Roche,
Germany). The following day, the pseudovirions were diluted in
DMEM (1:5000) and mixed with the sera at different dilutions
(Psv/serum). After 15 min incubation at room temperature, themedium of the 293TT cells was replaced with 200 μl of the
pseudovirion solution. As a control, cells were incubated with
pseudovirions alone (Psv/alone) or with pseudovirions in the
presence of a known neutralizing polyclonal antiserum specific
for HPV 16 (Psv/Ab). Detection of SEAP in cell culture
supernatant was performed 5 days later with the chemilumines-
cent SEAP Reporter Gene Assay (Roche, Germany) following
the manufacturer's instructions. To calculate the percent
neutralization, the differences were normalized between the
Psv/alone control and the pseudovirions incubated with the sera
(Psv/alone−Psv/serum) to the difference between the signals of
the controls (Psv/alone−Psv/Ab).
ELISPOT assay
96-Well MultiScreen IP sterile plates (MAIPS, Millipore,
Germany) were moistened with 50 μl 70% ethanol per well for
1 min and afterwards washed four times with PBS. The plates
were coated overnight at 4 °C with 600 ng anti-mouse IFN-γ
capture antibody (clone R4-6A2; BD Pharmingen, Germany)
per well diluted in 100 μl PBS. On the next day, the plates were
washed four times with PBS and blocked with 100 μl RPMI
(Sigma, Germany), supplemented with 10% FCS (Gibco BRL,
Germany) and 1% penicillin/streptomycin (Life Technologies,
Germany) per well for 2 h at 37 °C. The splenocytes were
counted and seeded in quadruplicates (BALB/c) or triplicates
(C57BL/6) in a twofold dilution series from 200,000 to 25,000
cells per well. As a positive control, cells of one dilution series
were incubated with 200 ng pokeweed mitogen (Sigma,
Germany) per well and background levels were obtained by
incubating the cells with medium only. The third series of
dilutions was incubated with 5 μg VLPs per well if BALB/c- or
0.2 μM L1-peptide if C57BL/6 mice were analyzed. In the case
of BALB/c mice, to the cells of the fourth dilution series, a mock
control (VLP purification from insect cells expressing L2 instead
of L1) was added to exclude that the CTLs recognize
contaminating insect cell proteins. Subsequently, the plates
were incubated at 37 °C for 16–18 h. The cells were then
removed by thoroughly washing the plates four times with PBS/
0.01% Tween-20. As a detection antibody, biotinylated anti-
mouse IFN-γ antibody (clone XMG1.2, BD Pharmingen,
Germany) was diluted in PBS, sterile filtered and 20 ng per
well were added to the plates for 2 to 3 h at 4 °C. After washing
six times with PBS/0.01% Tween-20, the plates were incubated
with 100 μl streptavidin–alkaline phosphatase (BD Pharmingen,
Germany) in a 1:1000 dilution in PBS for 30 min at room
temperature. Finally, the plates were washed three times with
PBS/0.01% Tween-20 followed by three washes with PBS.
100 μl 5-bromo-4-chloro-3-indolylphosphate (BCIP/nitro blue
tetrazolium liquid substrate system, Sigma, Germany) were then
added for 5 to 10 min. The reaction was stopped by rinsing the
plates with water after appearance of the spots. The quantifica-
tion of the spots was performed using an ELISPOT reader
(Elispot Reader System ELR02, AID GmbH, Germany). The
number of spots in the background control wells was subtracted
from the values of wells incubated with peptide. Mice were
defined to be positive in ELISPOT assay if the number of
387N. Thönes, M. Müller / Virology 369 (2007) 375–388IFN-γ spots per 1*106 cells was higher than the cutoff value,
which was calculated as the average of IFN-γ spots per 1*106
cells in negative control mice plus three times the standard
deviation.
Statistical analysis
Data sets were compared using the Wilcoxon rank sum test.
A p value below 0.05 was considered as statistically significant.
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